Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 1;160(6):646-650.
doi: 10.1001/jamadermatol.2024.0468.

Current State of Dermatology Mobile Applications With Artificial Intelligence Features

Affiliations
Review

Current State of Dermatology Mobile Applications With Artificial Intelligence Features

Shannon Wongvibulsin et al. JAMA Dermatol. .

Erratum in

  • Error in Table.
    [No authors listed] [No authors listed] JAMA Dermatol. 2024 Jun 1;160(6):688. doi: 10.1001/jamadermatol.2024.1011. JAMA Dermatol. 2024. PMID: 38630467 Free PMC article. No abstract available.
  • Error in Study Type.
    [No authors listed] [No authors listed] JAMA Dermatol. 2024 Jun 1;160(6):688. doi: 10.1001/jamadermatol.2024.1342. JAMA Dermatol. 2024. PMID: 38717756 Free PMC article. No abstract available.

Abstract

Importance: With advancements in mobile technology and artificial intelligence (AI) methods, there has been a substantial surge in the availability of direct-to-consumer mobile applications (apps) claiming to aid in the assessment and management of diverse skin conditions. Despite widespread patient downloads, these apps exhibit limited evidence supporting their efficacy.

Objective: To identify and characterize current English-language AI dermatology mobile apps available for download, focusing on aspects such as purpose, supporting evidence, regulatory status, clinician input, data privacy measures, and use of image data.

Evidence review: In this cross-sectional study, both Apple and Android mobile app stores were systematically searched for dermatology-related apps that use AI algorithms. Each app's purpose, target audience, evidence-based claims, algorithm details, data availability, clinician input during development, and data usage privacy policies were evaluated.

Findings: A total of 909 apps were initially identified. Following the removal of 518 duplicates, 391 apps remained. Subsequent review excluded 350 apps due to nonmedical nature, non-English languages, absence of AI features, or unavailability, ultimately leaving 41 apps for detailed analysis. The findings revealed several concerning aspects of the current landscape of AI apps in dermatology. Notably, none of the apps were approved by the US Food and Drug Administration, and only 2 of the apps included disclaimers for the lack of regulatory approval. Overall, the study found that these apps lack supporting evidence, input from clinicians and/or dermatologists, and transparency in algorithm development, data usage, and user privacy.

Conclusions and relevance: This cross-sectional study determined that although AI dermatology mobile apps hold promise for improving access to care and patient outcomes, in their current state, they may pose harm due to potential risks, lack of consistent validation, and misleading user communication. Addressing challenges in efficacy, safety, and transparency through effective regulation, validation, and standardized evaluation criteria is essential to harness the benefits of these apps while minimizing risks.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Daneshjou reported stock options from Revea and MDalgorithms, as well as personal fees from Pfizer, Frazier Healthcare Partners, and L'Oreal outside the submitted work; in addition, Dr Daneshjou had a patent for 17/937 714 pending and was a member of American Academy of Dermatology (AAD) Augmented Intelligence Committee. Dr Rotemberg reported personal fees from Excite International and grants from the National Institutes of Health (NIH) outside the submitted work, as well as being a member of the board of directors of the Society of Imaging Informatics in Medicine and the deputy chair of the Augmented Intelligence Committee of the AAD. No other disclosures were reported.

Figures

Figure.
Figure.. Characteristics of Dermatology Artificial Intelligence (AI) Applications
Only 5 applications (apps) had supporting evidence in the form of peer-reviewed journal publications. Only 4 apps had disclosure on CE (Conformité Européenne) Mark or US Food and Drug Administration approval status. Less than half of the apps had dermatologist input, and nearly half of the apps did not specify how user images can be used.

References

    1. Brewer AC, Endly DC, Henley J, et al. . Mobile applications in dermatology. JAMA Dermatol. 2013;149(11):1300-1304. doi:10.1001/jamadermatol.2013.5517 - DOI - PubMed
    1. Sun MD, Kentley J, Mehta P, Dusza S, Halpern AC, Rotemberg V. Accuracy of commercially available smartphone applications for the detection of melanoma. Br J Dermatol. 2022;186(4):744-746. doi:10.1111/bjd.20903 - DOI - PMC - PubMed
    1. Freeman K, Dinnes J, Chuchu N, et al. . Algorithm based smartphone apps to assess risk of skin cancer in adults: systematic review of diagnostic accuracy studies. BMJ. 2020;368:m127. doi:10.1136/bmj.m127 - DOI - PMC - PubMed
    1. Abbasi J. Artificial intelligence-based skin cancer phone apps unreliable. JAMA. 2020;323(14):1336. doi:10.1001/jama.2020.4543 - DOI - PubMed
    1. Matin RN, Dinnes J. AI-based smartphone apps for risk assessment of skin cancer need more evaluation and better regulation. Br J Cancer. 2021;124(11):1749-1750. doi:10.1038/s41416-021-01302-3 - DOI - PMC - PubMed